{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:29:22Z","timestamp":1773286162873,"version":"3.50.1"},"reference-count":21,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1507\/endocrj.ej12-0220","type":"journal-article","created":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T05:00:43Z","timestamp":1343365243000},"page":"1131-1136","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy"],"prefix":"10.1507","volume":"59","author":[{"given":"Mitsuyoshi","family":"Takahara","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Shiraiwa","sequence":"additional","affiliation":[{"name":"Shiraiwa Medical Clinic, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Katakami","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taka-aki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, et al. (2008) Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. <i>Lancet<\/i> 371: 1073-1084.","DOI":"10.1016\/S0140-6736(08)60485-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Fritsche A, Schweitzer MA and Haring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. <i>Ann Intern Med<\/i> 138: 952-959.","DOI":"10.7326\/0003-4819-138-12-200306170-00006"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, et al. (2007) Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. <i>N Engl J Med<\/i> 357: 1716-1730.","DOI":"10.1056\/NEJMoa075392"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. <i>Lancet<\/i> 368: 1696-1705.","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"5","unstructured":"5. The Japan Diabetes Society (2010) Evidence-based Practice Guideline for the Treatment of Diabetes in Japan. Nankodo Co., Ltd., Tokyo."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Schlichtkrull J, Munck O and Jersild M (1965) The M-Valve, an Index of Blood-Sugar Control in Diabetics. <i>Acta Med Scand<\/i> 177: 95-102.","DOI":"10.1111\/j.0954-6820.1965.tb01810.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan : From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. <i>J Diabetes Invest<\/i> 3: 39-40.","DOI":"10.1111\/j.2040-1124.2012.00207.x"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0633-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, et al. (2010) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. <i>Diabetes Obes Metab<\/i> 12: 167-177.","DOI":"10.1111\/j.1463-1326.2009.01173.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"12. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, et al. (2009) Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. <i>Diabetes Obes Metab<\/i> 11: 1145-1152.","DOI":"10.1111\/j.1463-1326.2009.01124.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"13. Karagiannis T, Paschos P, Paletas K, Matthews DR and Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. <i>BMJ<\/i> 344: e1369.","DOI":"10.1136\/bmj.e1369"},{"key":"12","doi-asserted-by":"crossref","unstructured":"14. Chung HS and Lee MK (2011) Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus. <i>Diabetes Metab J<\/i> 35: 411-417.","DOI":"10.4093\/dmj.2011.35.4.411"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.14.1681"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0063"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.12.1830"},{"key":"16","doi-asserted-by":"crossref","unstructured":"18. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, et al. (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. <i>Diabetologia<\/i> 39: 1577-1583.","DOI":"10.1007\/s001250050617"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.6.920"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12131-1"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1882"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.11.4053"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.5551\/jat.7666"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/59\/12\/59_EJ12-0220\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:32:47Z","timestamp":1618295567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/59\/12\/59_EJ12-0220\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej12-0220","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}